JILL HUDE: Open Payments
NPI 1568419489 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$848 in 40 payments from 13 companies in 2025. Trend: 2023 $303 · 2024 $736 · 2025 $848
Food & beverage: $848
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 8 | $150 |
| UCB, Inc. | 4 | $107 |
| Novartis Pharmaceuticals Corporation | 4 | $84 |
| Botanix SB Inc | 3 | $72 |
| ABBVIE INC. | 3 | $70 |
| Regeneron Healthcare Solutions, Inc. | 3 | $68 |
| LEO Pharma Inc. | 3 | $61 |
| Galderma Laboratories, L.P. | 3 | $54 |
| Incyte Corporation | 2 | $52 |
| Amgen Inc. | 3 | $52 |
Products named: TREMFYA, Bimzelx, SOFDRA, DUPIXENT, COSENTYX, ADBRY, NEMLUVIO, OPZELURA.
Industry payments across TX — which companies pay providers there.
